FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Emory grant aid suspended over GSK payments

Tools

Suspicions over physician payments means Emory University School of Medicine will not be touching its $9.3 million NIH grant for a while. 

Senator Chuck Grassley said that faculty in the medical school's psychiatry department agreed to keep consulting payments from GlaxoSmithKline to less than $10,000 each year, but failed to do so. In fact, Charles Nemeroff received $70,000 from GSK, bringing the total in payments to upwards of a half million dollars, which Nemeroff failed to report.

The grant has three years remaining, but NIH will keep it on hold until the university resolves its conflicts of interest and ensures that it's researcher physicians report payments from drug companies accurately.

It will be interesting to see which universities, researchers and drug companies Grassley picks for his next examples. 

- see the Wall Street Journal blog entry 

Related Articles:
NIH slaps Emory with new grant rules
Emory doc hid $1.2M in pharma payments
Harvard officials to probe psychiatrists' drug payments
Americans want doc payments disclosed

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:
Be the first to comment
More stories about GlaxoSmithKline   Payments   Emory University   Charles Nemeroff  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.